Answers are grounded in this paper and cite their sources.
Patients with lymphoid malignancies are at a higher risk of coronavirus disease 2019 (COVID-19) infection due to their immunocompromised state and results in higher mortality rates in these patients. Anti-CD 20 therapy is one of the leading causes of immunosuppression that worsens in COVID-19 cases. COVID-19 vaccines, on the other hand, appear to be less beneficial to these patients. App-ropriate treatment and recommendations are required for these COVID-19 patients with lymphoid malignancies.
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: